Genome Editing companies

Key Genome Editing Market Players:

 

The international market is severely united with the presence of organizations, such as Intellia Therapeutics, Editas Medicine, and CRISPR Therapeutics, jointly dominating through FDA-accepted therapies, along with tactical collaborations. Besides, players from Europe, including Cellectis and Merck KGaA focus on TALENs and reagents, while Asia-based organizations, such as BGI Group, effectively target agriculture-specific CRISPR. Meanwhile, essential initiatives, including emerging market expansion, along with vertical implementation, are positively impacting the market development globally. For instance, CSIR-IGIB’s cost-effective CRISPR in India and Thermo Fisher’s vector manufacturing are responsible for uplifting the market.

Here is a list of key players operating in the global market:

Company Name	Country	Industry Focus	Market Share (2024)
CRISPR Therapeutics	U.S.	CRISPR-based therapeutics (e.g., Casgevy for sickle cell disease)	18.9%
Editas Medicine	U.S.	CRISPR-Cas9 therapies for genetic disorders (e.g., EDIT-101 for blindness)	12.1%
Intellia Therapeutics	U.S.	In vivo CRISPR delivery (e.g., NTLA-2001 for ATTR amyloidosis)	10.5%
Vertex Pharmaceuticals	U.S.	Gene-editing partnerships (e.g., Casgevy with CRISPR Therapeutics)	9.3%
Thermo Fisher Scientific	U.S.	Genome editing tools & viral vectors	8.7%
Merck KGaA	Germany	CRISPR reagents & gene-editing kits	xx%
Sangamo Therapeutics	U.S.	Zinc Finger Nuclease (ZFN) technology for gene therapy	xx%
Precision BioSciences	U.S.	ARCUS genome editing platform for CAR-T therapies	xx%
Caribou Biosciences	U.S.	CRISPR-Cas12a therapeutics (e.g., CB-010 for lymphoma)	xx%
Beam Therapeutics	U.S.	Base editing (e.g., BEAM-101 for sickle cell disease)	xx%
Cellectis	France	TALEN-based gene editing for oncology	xx%
Lonza Group	Switzerland	Contract manufacturing for viral vectors & cell therapies	xx%
GenScript Biotech	China	CRISPR reagents & synthetic biology tools	xx%
BGI Group	China	Agricultural & biomedical CRISPR applications	xx%
CSIR-IGIB	India	Affordable CRISPR diagnostics & therapeutics	xx%

 Below are the areas covered for each company in the genome editing market:

• Company Overview
• Business Strategy
• Key Product Offerings
• Financial Performance
• Key Performance Indicators
• Risk Analysis
• Recent Development
• Regional Presence
• SWOT Analysis